CORAL SPRINGS, Florida, October 25, 2013 /PRNewswire/ --
Chanticleer Holdings, Inc. (NASDAQ: HOTR) Chanticleer Holdings (NASDAQ: HOTR, HOTRU) is a business operator focused on expanding the Hooters casual dining restaurant brand in international markets. Chanticleer currently has rights to develop and operate Hooters restaurants in South Africa and has joint ventured with the current franchisee in Australia. The company also has franchise rights to develop Hungary and parts of Brazil while evaluating several additional opportunities internationally. Get a comprehensive report on HOTR at the following link: http://bit.ly/FeaturedReport-HOTR
Capstone Turbine Corp. (NASDAQ: CPST) develops, manufactures, markets and services microturbine technology solutions for use in stationary distributed power generation applications, including cogeneration (combined heat and power (CHP), integrated combined heat and power (ICHP), and combined cooling, heat and power (CCHP)), renewable energy, natural resources and critical power supply. In addition, its microturbines can be used as battery charging generators for hybrid electric vehicle applications. Microturbines allow customers to produce power on-site in parallel with the electric grid or stand alone when no utility grid is available. Several technologies are used to provide on-site power generation (distributed generation), such as reciprocating engines, solar power, wind powered systems and fuel cells. Get a comprehensive report on CPST at the following link: http://bit.ly/FeaturedReport-CPST
Dynavax Technologies Corp. (NASDAQ: DVAX) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines. The Company's pipeline of product candidates includes HEPLISAV, its autoimmune program partnered with GlaxoSmithKline (GSK), its therapy for asthma partnered with AstraZeneca AB (AstraZeneca), and clinical-stage programs for its Universal Flu vaccine and hepatitis B therapy. As of December 31, 2011, its intellectual property portfolio included 18 issued United States patents, claiming compositions and formulations of immunostimulatory sequences (ISS) and Internal Revenue Service (IRS), their methods of use or processes for their manufacture. Find out what is new at DVAX at the following link: http://bit.ly/FeaturedReport-DVAX
Dendreon Corporation (NASDAQ: DNDN) Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Receptor Potential, sub-family M (TRPM8). Find out what is new at DNDN at the following link: http://bit.ly/FeaturedReport-DNDN
PennyStockPress.com News Alerts: Get small and micro-cap alerts in real time by joining PennyStockPress SMS alerts send "PennyPress" to 63566 or join our limited time free VIP membership at http://PennyStockPress.com http://www.otcbbjournal.com/
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG was not compensated by any public company mentioned herein to disseminate this press release.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
|SOURCE FN Media Group, LLC|
Copyright©2012 PR Newswire.
All rights reserved